Global gene expression profiling of PAX‐FKHR fusion‐positive alveolar and PAX‐FKHR fusion‐negative embryonal rhabdomyosarcomas
- 11 May 2007
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 212 (2) , 143-151
- https://doi.org/10.1002/path.2170
Abstract
Paediatric rhabdomyosarcomas (RMS) are classified into two major subtypes based on histological appearance, embryonal (ERMS) and alveolar (ARMS), but this clinically critical distinction is often difficult on morphological grounds alone. ARMS, the more aggressive subtype, is associated in most cases with unique recurrent translocations fusing the PAX3 or PAX7 transcription factor genes to FKHR. In contrast, ERMS lacks unique genetic alterations. To identify novel diagnostic markers and potential therapeutic targets, we analysed the global gene expression profiles of these two RMS subtypes in 23 ARMS (16 PAX3‐FKHR, 7 PAX7‐FKHR) and 15 ERMS (all PAX‐FKHR‐negative) using Affymetrix HG‐U133A oligonucleotide arrays. A statistically stringent supervised comparison of the ARMS and ERMS expression profiles revealed 121 genes that were significantly differentially expressed, of which 112 were higher in ARMS, including genes of interest as potential diagnostic markers or therapeutic targets, such as CNR1, PIPOX (sarcosine oxidase), and TFAPβ. Interestingly, many known or putative downstream targets of PAX3‐FKHR were highly overexpressed in ARMS relative to ERMS, including CNR1, DCX, ABAT, ASS, JAKMIP2, DKFZp762M127, and NRCAM. We validated the highly differential expression of five genes, including CNR1, DKFZp762M127, DCX, PIPOX, and FOXF1 in ARMS relative to ERMS by quantitative RT‐PCR on an independent set of samples. Finally, we developed a ten‐gene microarray‐based predictor that distinguished ARMS from ERMS with approximately 95% accuracy both in our data by cross‐validation and in an independent validation using a published dataset of 26 samples. The gene expression signature of ARMS provides a source of potential diagnostic markers, therapeutic targets, and PAX‐FKHR downstream genes, and can be used to reliably distinguish these sarcomas from ERMS. Copyright © 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 42 references indexed in Scilit:
- Identification of a PAX-FKHR Gene Expression Signature that Defines Molecular Classes and Determines the Prognosis of Alveolar RhabdomyosarcomasCancer Research, 2006
- Global Gene Expression Profiling of Pleural Mesotheliomas: Overexpression of Aurora Kinases and P16/CDKN2A Deletion as Prognostic Factors and Critical Evaluation of Microarray-Based Prognostic PredictionCancer Research, 2006
- Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphomaFEBS Letters, 2005
- Profiling the molecular difference between Patched- and p53-dependent rhabdomyosarcomaOncogene, 2004
- A new role for BMP5 during limb development acting through the synergic activation of Smad and MAPK pathwaysDevelopmental Biology, 2004
- Profiling and functional annotation of mRNA gene expression in pediatric rhabdomyosarcoma and Ewing's sarcomaInternational Journal of Cancer, 2004
- Exploration, normalization, and summaries of high density oligonucleotide array probe level dataBiostatistics, 2003
- Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?British Journal of Cancer, 2001
- Rhabdomyosarcoma – working out the pathwaysOncogene, 1999
- Allelotype of pediatric rhabdomyosarcomaOncogene, 1997